Cardiome Pharma (CRME) Misses Q2 View By 9c
More News related to CRME
- Cardiome Pharma's (CRME) CEO, Rieder, Subject to Margin Call
- Cardiome Discloses Chairman And CEO's Involuntary Share Sale
- Cardiome Reports Third Quarter Results
- Cardiome Pharma (CRME) Misses Q2 View By 9c
- Unusual 11 Mid-Day Movers: CHIP, BZH, RHD, LCC Higher; BWTR, SIRF, CRME, URRE Lower
Cardiome Pharma (Nasdaq: CRME) reports a Q2 loss of $0.28, 9 cents below the analyst estimate of ($0.19).
Cardiome Pharma Corp., through its subsidiaries, operates as a life sciences company that focuses on developing drugs to treat or prevent cardiovascular diseases.
Sign up at EasyStockAlerts.com & Make Money Today!
Related Categories
EarningsStocks Mentioned
+0.21Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
